Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.0%

7 terminated/withdrawn out of 87 trials

Success Rate

90.1%

+3.6% vs industry average

Late-Stage Pipeline

37%

32 trials in Phase 3/4

Results Transparency

13%

8 of 64 completed trials have results

Key Signals

8 recruiting8 with results6 terminated

Enrollment Performance

Analytics

Phase 3

22(31.4%)

Phase 1

20(28.6%)

Phase 2

10(14.3%)

Phase 4

10(14.3%)

Early Phase 1

4(5.7%)

N/A

4(5.7%)

70Total

Phase 3(22)

Phase 1(20)

Phase 2(10)

Phase 4(10)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (87)

Showing 20 of 87 trials

NCT04557059Phase 3Active Not Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Role: lead

NCT05049798Active Not Recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

Role: lead

NCT05160584Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Role: lead

NCT04608318Phase 3Active Not Recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Role: collaborator

NCT07002320Phase 1Recruiting

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT07107529Phase 2Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Role: collaborator

NCT06856902Not ApplicableRecruiting

BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe

Role: collaborator

NCT06544616Phase 2Active Not Recruiting

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Role: lead

NCT04108468Phase 3Completed

GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA

Role: collaborator

NCT05140525Phase 3Recruiting

Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

Role: collaborator

NCT05572229Phase 2Recruiting

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Role: collaborator

NCT05328297Phase 2Completed

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

Role: lead

NCT05550519Early Phase 1Withdrawn

A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment

Role: lead

NCT03882255Phase 1Completed

A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

Role: lead

NCT05552196Phase 1Completed

A Study of Ponesimod in Healthy Adult Participants

Role: lead

NCT04566926Phase 1Terminated

A Study of JNJ-64140284 in Healthy Male Participants

Role: lead

NCT06632236Phase 1Recruiting

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Role: collaborator

NCT03903835Phase 3Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Role: collaborator

NCT04388501Phase 1Completed

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

Role: lead

NCT05706753Phase 1Completed

A Study of Milvexian in Healthy Adult Females

Role: lead